NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

Study May Proceed letter received from FDAIND preclinical requirements are consistent with studies already in progress to support treatment of Bipolar DepressionPotential to initiate registrational...

Related Keywords

Stephen Willard ,Nrxp Nrx Pharmaceuticals ,Nrx Pharmaceuticals ,Division Of Psychiatry Products ,Prnewswire Nrx Pharmaceuticals Inc ,Source Nrx Pharmaceuticals ,Division Of Anesthesiology ,Nasdaq ,Company Quarterly Reports On Form ,Alvogen Pharmaceuticals ,Exchange Commission ,Addiction Medicine ,Pain Medicine ,Investigational New Drug ,Psychiatry Products ,Bipolar Depression ,Chronic Pain ,Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Markets ,